메뉴 건너뛰기




Volumn 10, Issue 2, 2010, Pages 176-191

Gefitinib targets EGFR dimerization and ERK1/2 phosphorylation to inhibit pleural mesothelioma cell proliferation

Author keywords

EGFR targeting; Gefitinib; Human malignant pleural mesothelioma cells; Preclinical chemotherapy

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; THYMIDINE;

EID: 77950673755     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800910791054130     Document Type: Article
Times cited : (23)

References (45)
  • 1
    • 56649103705 scopus 로고    scopus 로고
    • Pathogenesis of malignant pleural mesothelioma and the role of environmental and genetic factors
    • Weiner, S. J.; Neragi-Miandoab, S. Pathogenesis of malignant pleural mesothelioma and the role of environmental and genetic factors. J. Cancer Res. Clin. Oncol. 2009, 135, 15-27.
    • (2009) J. Cancer Res. Clin. Oncol. , vol.135 , pp. 15-27
    • Weiner, S.J.1    Neragi-Miandoab, S.2
  • 3
    • 3042623428 scopus 로고    scopus 로고
    • The effect of extent of local resection on patterns of disease progression in malignant pleural mesothelioma
    • Stewart, D. J.; Martin-Ucar, A.; Pilling, J. E.; Edwards, J. G.; O'byrne, K. J.; Waller, D. A. The effect of extent of local resection on patterns of disease progression in malignant pleural mesothelioma. Ann. Thorac. Surg. 2004, 78, 245-252.
    • (2004) Ann. Thorac. Surg. , vol.78 , pp. 245-252
    • Stewart, D.J.1    Martin-Ucar, A.2    Pilling, J.E.3    Edwards, J.G.4    O'Byrne, K.J.5    Waller, D.A.6
  • 4
    • 3142779111 scopus 로고    scopus 로고
    • Radiation therapy of mesothelioma: The Heidelberg experience and future aspects
    • Zierhut, D.; Gutwein, S.; Munter, M. W.; Woger, H.; Debus, J. Radiation therapy of mesothelioma: the Heidelberg experience and future aspects. Lung Cancer 2004, 45(Suppl 1), S85-91.
    • (2004) Lung Cancer , vol.45 , Issue.SUPPL. 1
    • Zierhut, D.1    Gutwein, S.2    Munter, M.W.3    Woger, H.4    Debus, J.5
  • 5
    • 16244362744 scopus 로고    scopus 로고
    • Chemotherapy options and new advances in malignant pleural mesothelioma
    • Steele, J. P.; Klabatsa, A. Chemotherapy options and new advances in malignant pleural mesothelioma. Ann. Oncol. 2005, 16, 345-351.
    • (2005) Ann. Oncol. , vol.16 , pp. 345-351
    • Steele, J.P.1    Klabatsa, A.2
  • 6
    • 0036837690 scopus 로고    scopus 로고
    • Activity of chemotherapy and immunotherapy on malignant mesothelioma: A systematic review of the literature with meta-analysis
    • Berghmans, T.; Paesmans, M.; Lalami, Y.; Louviaux, I.; Luce, S.; Mascaux, C.; Meert, A. P.; Sculier, J. P. Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer 2002, 38, 111-121.
    • (2002) Lung Cancer , vol.38 , pp. 111-121
    • Berghmans, T.1    Paesmans, M.2    Lalami, Y.3    Louviaux, I.4    Luce, S.5    Mascaux, C.6    Meert, A.P.7    Sculier, J.P.8
  • 8
    • 34547765871 scopus 로고    scopus 로고
    • Preliminary data suggestive of a novel translational approach to mesothelioma treatment: Imatinib mesylate with gemcitabine or pemetrexed
    • Bertino, P.; Porta, C.; Barbone, D.; Germano, S.; Busacca, S.; Pinato, S.; Tassi, G.; Favoni, R.; Gaudino, G.; Mutti, L. Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed. Thorax 2007, 62, 690-695.
    • (2007) Thorax , vol.62 , pp. 690-695
    • Bertino, P.1    Porta, C.2    Barbone, D.3    Germano, S.4    Busacca, S.5    Pinato, S.6    Tassi, G.7    Favoni, R.8    Gaudino, G.9    Mutti, L.10
  • 9
    • 38949184992 scopus 로고    scopus 로고
    • Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenografts
    • Bertino, P.; Piccardi, F.; Porta, C.; Favoni, R.; Cilli, M.; Mutti, L.; Gaudino, G. Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenografts. Clin. Cancer Res. 2008, 14, 541-548.
    • (2008) Clin. Cancer Res. , vol.14 , pp. 541-548
    • Bertino, P.1    Piccardi, F.2    Porta, C.3    Favoni, R.4    Cilli, M.5    Mutti, L.6    Gaudino, G.7
  • 10
    • 0025330611 scopus 로고
    • Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody
    • Dazzi, H.; Hasleton, P. S.; Thatcher, N.; Wilkes, S.; Swindell, R.; Chatterjee, A. K. Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody. Br. J. Cancer 1990, 61, 924-926.
    • (1990) Br. J. Cancer , vol.61 , pp. 924-926
    • Dazzi, H.1    Hasleton, P.S.2    Thatcher, N.3    Wilkes, S.4    Swindell, R.5    Chatterjee, A.K.6
  • 11
    • 0023484719 scopus 로고
    • Comparison of production of transforming growth factor-beta and platelet-derived growth factor by normal human mesothelial cells and mesothelioma cell lines
    • Gerwin, B. I.; Lechner, J. F.; Reddel, R. R.; Roberts, A. B.; Robbins, K. C.; Gabrielson, E. W.; Harris, C. C. Comparison of production of transforming growth factor-beta and platelet-derived growth factor by normal human mesothelial cells and mesothelioma cell lines. Cancer Res. 1987, 47, 6180-6184.
    • (1987) Cancer Res. , vol.47 , pp. 6180-6184
    • Gerwin, B.I.1    Lechner, J.F.2    Reddel, R.R.3    Roberts, A.B.4    Robbins, K.C.5    Gabrielson, E.W.6    Harris, C.C.7
  • 12
    • 0027195940 scopus 로고
    • Normal human mesothelial cells and mesothelioma cell lines express insulin-like growth factor I and associated molecules
    • Lee, T. C.; Zhang, Y.; Aston, C.; Hintz, R.; Jagirdar, J.; Perle, M. A.; Burt, M.; Rom, W. N. Normal human mesothelial cells and mesothelioma cell lines express insulin-like growth factor I and associated molecules. Cancer Res. 1993, 53, 2858-2864.
    • (1993) Cancer Res. , vol.53 , pp. 2858-2864
    • Lee, T.C.1    Zhang, Y.2    Aston, C.3    Hintz, R.4    Jagirdar, J.5    Perle, M.A.6    Burt, M.7    Rom, W.N.8
  • 13
    • 0026576726 scopus 로고
    • Insulin-like growth factors and cancer
    • Macaulay, V. M. Insulin-like growth factors and cancer. Br. J. Cancer 1992, 65, 311-320.
    • (1992) Br. J. Cancer , vol.65 , pp. 311-320
    • Macaulay, V.M.1
  • 17
    • 0035884231 scopus 로고    scopus 로고
    • The epidermal growth factor receptor: From mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia
    • Arteaga, C. L. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J. Clin. Oncol. 2001, 19, 32S-40S.
    • (2001) J. Clin. Oncol. , vol.19
    • Arteaga, C.L.1
  • 18
    • 0031887743 scopus 로고    scopus 로고
    • Protein kinase inhibitors: The tyrosine-specific protein kinases
    • Lawrence, D. S.; Niu, J. Protein kinase inhibitors: the tyrosine-specific protein kinases. Pharmacol. Ther. 1998, 77, 81-114.
    • (1998) Pharmacol. Ther. , vol.77 , pp. 81-114
    • Lawrence, D.S.1    Niu, J.2
  • 19
    • 0035892346 scopus 로고    scopus 로고
    • ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression
    • Anderson, N. G.; Ahmad, T.; Chan, K.; Dobson, R.; Bundred, N. J. ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression. Int. J. Cancer 2001, 94, 774-782.
    • (2001) Int. J. Cancer , vol.94 , pp. 774-782
    • Anderson, N.G.1    Ahmad, T.2    Chan, K.3    Dobson, R.4    Bundred, N.J.5
  • 20
    • 0034068319 scopus 로고    scopus 로고
    • Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor
    • Ciardiello, F.; Caputo, R.; Bianco, R.; Damiano, V.; Pomatico, G.; De Placido, S.; Bianco, A. R.; Tortora, G. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin. Cancer Res. 2000, 6, 2053-2063.
    • (2000) Clin. Cancer Res. , vol.6 , pp. 2053-2063
    • Ciardiello, F.1    Caputo, R.2    Bianco, R.3    Damiano, V.4    Pomatico, G.5    De Placido, S.6    Bianco, A.R.7    Tortora, G.8
  • 22
    • 0037109014 scopus 로고    scopus 로고
    • ZD1839 (Iressa): An orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy
    • Wakeling, A. E.; Guy, S. P.; Woodburn, J. R.; Ashton, S. E.; Curry, B. J.; Barker, A. J.; Gibson, K. H. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 2002, 62, 5749-5754.
    • (2002) Cancer Res. , vol.62 , pp. 5749-5754
    • Wakeling, A.E.1    Guy, S.P.2    Woodburn, J.R.3    Ashton, S.E.4    Curry, B.J.5    Barker, A.J.6    Gibson, K.H.7
  • 23
    • 0034489914 scopus 로고    scopus 로고
    • Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase
    • Sirotnak, F. M.; Zakowski, M. F.; Miller, V. A.; Scher, H. I.; Kris, M. G. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin. Cancer Res. 2000, 6, 4885-4892.
    • (2000) Clin. Cancer Res. , vol.6 , pp. 4885-4892
    • Sirotnak, F.M.1    Zakowski, M.F.2    Miller, V.A.3    Scher, H.I.4    Kris, M.G.5
  • 24
    • 0037105665 scopus 로고    scopus 로고
    • Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma
    • Janne, P. A.; Taffaro, M. L.; Salgia, R.; Johnson, B. E. Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. Cancer Res. 2002, 62, 5242-5247.
    • (2002) Cancer Res. , vol.62 , pp. 5242-5247
    • Janne, P.A.1    Taffaro, M.L.2    Salgia, R.3    Johnson, B.E.4
  • 25
    • 0036178251 scopus 로고    scopus 로고
    • New approaches for mesothelioma: Biologics, vaccines, gene therapy, and other novel agents
    • Nowak, A. K.; Lake, R. A.; Kindler, H. L.; Robinson, B. W. New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents. Semin. Oncol. 2002, 29, 82-96.
    • (2002) Semin. Oncol. , vol.29 , pp. 82-96
    • Nowak, A.K.1    Lake, R.A.2    Kindler, H.L.3    Robinson, B.W.4
  • 27
    • 0026608576 scopus 로고
    • Hematopoietic growth factors secreted by seven human pleural mesothelioma cell lines: Interleukin-6 production as a common feature
    • Schmitter, D.; Lauber, B.; Fagg, B.; Stahel, R. A. Hematopoietic growth factors secreted by seven human pleural mesothelioma cell lines: interleukin-6 production as a common feature. Int. J. Cancer 1992, 51, 296-301.
    • (1992) Int. J. Cancer , vol.51 , pp. 296-301
    • Schmitter, D.1    Lauber, B.2    Fagg, B.3    Stahel, R.A.4
  • 28
    • 0043209011 scopus 로고    scopus 로고
    • Enhanced effectiveness of last generation antiblastic compounds vs. cisplatin on malignant pleural mesothelioma cell lines
    • De Cupis, A.; Semino, C.; Pirani, P.; Loprevite, M.; Ardizzoni, A.; Favoni, R. E. Enhanced effectiveness of last generation antiblastic compounds vs. cisplatin on malignant pleural mesothelioma cell lines. Eur. J. Pharmacol. 2003, 473, 83-95.
    • (2003) Eur. J. Pharmacol. , vol.473 , pp. 83-95
    • De Cupis, A.1    Semino, C.2    Pirani, P.3    Loprevite, M.4    Ardizzoni, A.5    Favoni, R.E.6
  • 29
    • 37349047939 scopus 로고    scopus 로고
    • 17beta-estradiol promotes breast cancer cell proliferation-inducing stromal cell-derived factor-1-mediated epidermal growth factor receptor transactivation: Reversal by gefitinib pretreatment
    • Pattarozzi, A.; Gatti, M.; Barbieri, F.; Wurth, R.; Porcile, C.; Lunardi, G.; Ratto, A.; Favoni, R.; Bajetto, A.; Ferrari, A.; Florio, T. 17beta-estradiol promotes breast cancer cell proliferation-inducing stromal cell-derived factor-1-mediated epidermal growth factor receptor transactivation: reversal by gefitinib pretreatment. Mol. Pharmacol. 2008, 73, 191-202.
    • (2008) Mol. Pharmacol. , vol.73 , pp. 191-202
    • Pattarozzi, A.1    Gatti, M.2    Barbieri, F.3    Wurth, R.4    Porcile, C.5    Lunardi, G.6    Ratto, A.7    Favoni, R.8    Bajetto, A.9    Ferrari, A.10    Florio, T.11
  • 31
    • 24944553762 scopus 로고    scopus 로고
    • Stromal cellderived factor-1alpha (SDF-1alpha/CXCL12) stimulates ovarian cancer cell growth through the EGF receptor transactivation
    • Porcile, C.; Bajetto, A.; Barbieri, F.; Barbero, S.; Bonavia, R.; Biglieri, M.; Pirani, P.; Florio, T.; Schettini, G. Stromal cellderived factor-1alpha (SDF-1alpha/CXCL12) stimulates ovarian cancer cell growth through the EGF receptor transactivation. Exp. Cell Res. 2005, 308, 241-253.
    • (2005) Exp. Cell Res. , vol.308 , pp. 241-253
    • Porcile, C.1    Bajetto, A.2    Barbieri, F.3    Barbero, S.4    Bonavia, R.5    Biglieri, M.6    Pirani, P.7    Florio, T.8    Schettini, G.9
  • 32
    • 0026496890 scopus 로고
    • Dopaminergic inhibition of DNA synthesis in pituitary tumor cells is associated with phosphotyrosine phosphatase activity
    • Florio, T.; Pan, M. G.; Newman, B.; Hershberger, R. E.; Civelli, O.; Stork, P. J. Dopaminergic inhibition of DNA synthesis in pituitary tumor cells is associated with phosphotyrosine phosphatase activity. J. Biol. Chem. 1992, 267, 24169-24172.
    • (1992) J. Biol. Chem. , vol.267 , pp. 24169-24172
    • Florio, T.1    Pan, M.G.2    Newman, B.3    Hershberger, R.E.4    Civelli, O.5    Stork, P.J.6
  • 35
    • 0034705479 scopus 로고    scopus 로고
    • Abrogation of nerve growth factor-induced terminal differentiation by ret oncogene involves perturbation of nuclear translocation of ERK
    • Colucci-D'Amato, G. L.; D'Alessio, A.; Califano, D.; Calì, G.; Rizzo, C.; Nitsch, L.; Santelli, G.; de Franciscis, V. Abrogation of nerve growth factor-induced terminal differentiation by ret oncogene involves perturbation of nuclear translocation of ERK. J. Biol. Chem. 2000, 275, 19306-19314.
    • (2000) J. Biol. Chem. , vol.275 , pp. 19306-19314
    • Colucci-D'Amato, G.L.1    D'Alessio, A.2    Califano, D.3    Calì, G.4    Rizzo, C.5    Nitsch, L.6    Santelli, G.7    De Franciscis, V.8
  • 36
    • 0242551370 scopus 로고    scopus 로고
    • Chronic activation of ERK and neurodegenerative diseases
    • Colucci-D'Amato, G. L.; Perrone-Campano, C.; di Porzio, U. Chronic activation of ERK and neurodegenerative diseases. BioEssay 2003, 25, 1085-1095.
    • (2003) BioEssay , vol.25 , pp. 1085-1095
    • Colucci-D'Amato, G.L.1    Perrone-Campano, C.2    Di Porzio, U.3
  • 37
    • 0037388251 scopus 로고    scopus 로고
    • ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells
    • Anido, J.; Matar, P.; Albanell, J.; Guzman, M.; Rojo, F.; Arribas, J.; Averbuch, S.; Baselga, J. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. Clin. Cancer Res. 2003, 9, 1274-1283.
    • (2003) Clin. Cancer Res. , vol.9 , pp. 1274-1283
    • Anido, J.1    Matar, P.2    Albanell, J.3    Guzman, M.4    Rojo, F.5    Arribas, J.6    Averbuch, S.7    Baselga, J.8
  • 38
    • 0033986112 scopus 로고    scopus 로고
    • Anticancer drug targets: Growth factors and growth factor signaling
    • Gibbs, J. B. Anticancer drug targets: growth factors and growth factor signaling. J. Clin. Invest. 2000, 105, 9-13.
    • (2000) J. Clin. Invest. , vol.105 , pp. 9-13
    • Gibbs, J.B.1
  • 39
    • 65849296369 scopus 로고    scopus 로고
    • Growth inhibition by tyrosine kinase inhibitors in mesothelioma cell lines
    • Nutt, J. E.; O'Toole K.; Gonzalez D.; Lunec, J. Growth inhibition by tyrosine kinase inhibitors in mesothelioma cell lines. Eur. J. Cancer 2009, 45(9), 1684-1691.
    • (2009) Eur. J. Cancer , vol.45 , Issue.9 , pp. 1684-1691
    • Nutt, J.E.1    O'Toole, K.2    Gonzalez, D.3    Lunec, J.4
  • 40
    • 0031974705 scopus 로고    scopus 로고
    • Therapeutic application of anti-growth factor receptor antibodies
    • Fan, Z.; Mendelsohn, J. Therapeutic application of anti-growth factor receptor antibodies. Curr. Opin. Oncol. 1998, 10, 67-73.
    • (1998) Curr. Opin. Oncol. , vol.10 , pp. 67-73
    • Fan, Z.1    Mendelsohn, J.2
  • 41
    • 0028106163 scopus 로고
    • Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor
    • Ward, W. H.; Cook, P. N.; Slater, A. M.; Davies, D. H.; Holdgate, G. A.; Green, L. R. Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor. Biochem. Pharmacol. 1994, 48, 659-666.
    • (1994) Biochem. Pharmacol. , vol.48 , pp. 659-666
    • Ward, W.H.1    Cook, P.N.2    Slater, A.M.3    Davies, D.H.4    Holdgate, G.A.5    Green, L.R.6
  • 42
    • 0036473508 scopus 로고    scopus 로고
    • Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD 1839 ("Iressa")
    • Sewell, J. M.; Macleod, K. G.; Ritchie, A.; Smyth, J. F.; Langdon, S. P. Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD 1839 ("Iressa"). Br. J. Cancer 2002, 86, 456-462.
    • (2002) Br. J. Cancer , vol.86 , pp. 456-462
    • Sewell, J.M.1    Macleod, K.G.2    Ritchie, A.3    Smyth, J.F.4    Langdon, S.P.5
  • 43
    • 0030801361 scopus 로고    scopus 로고
    • Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site
    • Arteaga, C. L.; Ramsey, T. T.; Shawver, L. K.; Guyer, C. A. Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site. J. Biol. Chem. 1997, 272, 23247-23254.
    • (1997) J. Biol. Chem. , vol.272 , pp. 23247-23254
    • Arteaga, C.L.1    Ramsey, T.T.2    Shawver, L.K.3    Guyer, C.A.4
  • 44
    • 0035423120 scopus 로고    scopus 로고
    • Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors
    • Lichtner, R. B.; Menrad, A.; Sommer, A.; Klar, U.; Schneider, M. R. Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors. Cancer Res. 2001, 61, 5790-5795.
    • (2001) Cancer Res. , vol.61 , pp. 5790-5795
    • Lichtner, R.B.1    Menrad, A.2    Sommer, A.3    Klar, U.4    Schneider, M.R.5
  • 45
    • 57349172709 scopus 로고    scopus 로고
    • Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib
    • Servidei, T.; Riccardi, A.; Mozzetti, S.; Ferlini, C.; Riccardi, R. Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib. Int. J. Cancer 2008, 123, 2939-2949.
    • (2008) Int. J. Cancer , vol.123 , pp. 2939-2949
    • Servidei, T.1    Riccardi, A.2    Mozzetti, S.3    Ferlini, C.4    Riccardi, R.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.